gastrointestinal tumors
Conditions
Interventions
Sponsors
Anqing Hospital of the PLA Navy
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years, gender unlimited, voluntary to participate in the experiment and sign the informed consent; 2. Pathologically confirmed advanced gastrointestinal tumors, including gastric adenocarcinoma (including adenocarcinoma of the gastroesophageal junction), colorectal cancer, biliary tract tumors, and liver/pancreas tumors; 3. Failure to receive standard treatment; 4. ECOG score: 0-2; 5. At least one lesion can be measured by CT, according to RECIST 1.1 criteria; 6. Expected to survive for at least 3 months; 7. Researchers evaluate the benefits; 8. Subjects voluntarily participated in the study and signed an informed consent form (ICF); 9. Good compliance is expected, and the efficacy and adverse reactions can be followed up according to the protocol requirements.
Exclusion criteria
Exclusion criteria: 1. Patients with severe allergic history or allergic constitution; 2. Pregnant or lactating patients; 3. Patients who have participated in other clinical trials and have not terminated the trial; 4. Patients with a definite tendency to gastrointestinal bleeding. Include the following: (1) Locally active ulcerative lesions, and fecal occult blood 2+; (2) Patients with history of black stool and hematemesis within 3 months; (3) Gastroscopy is required for patients with 1+ fecal occult blood and no surgical resection of the primary lesion of gastric tumor, such as ulcerative gastric cancer, and the main researcher of the center thinks that massive gastrointestinal bleeding may occur; 5. Received major surgical treatment, open biopsy or significant traumatic injury within 28 days prior to the grouping (specifically combined with clinical evaluation); 6. History of any active autoimmune disease or autoimmune disease, including but not limited to interstitial pneumonia, uveitis, inflammatory bowel disease, hepatitis, pituitary inflammation, vasculitis, systemic lupus erythematosus, etc.; 7. Patients whose imaging shows that the tumor has invaded important vascular peripherals or whose tumor is judged by the investigator to be highly likely to invade important vascular peripherals and cause fatal massive hemorrhage during the follow-up study; 8. Patients with any physical signs or history of bleeding, regardless of severity; Unhealed wounds, ulcers, or fractures in patients with any bleeding or bleeding events >=CTCAE grade 3 during the 4 weeks prior to enrollment; 9. Experienced arteriovenous thrombosis, such as cerebrovascular accident (including temporary ischemic attack), deep vein thrombosis and pulmonary embolism within 6 months; 10. Those who have a history of psychotropic substance abuse and cannot abstain or have mental disorders; 11. Patients with dysphagia or known drug absorption disorders; 12. The researchers considered other conditions unsuitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;security;objective response rate;disease control rate; | — |
Countries
China
Contacts
Public ContactQian Hong
Anqing Hospital of the PLA Navy
Outcome results
None listed